LAUSR

Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.

Sign Up to like & get
recommendations!
0 Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.e21146

Abstract: e21146Background: Acquired T790M mutation accounts for 50-60% of TKI resistant mechanism in EGFR mutation (+) NSCLC patients progressed after TKIs. Rebiopsy was recommend in these patients to detect the T790M mutation. Icotinib was a first-generation… read more here.

Keywords: icotinib therapy; rebiopsy; china; rebiopsy status ... See more keywords